Second interims analysis of the ARA Plus study – Breast Cancer (BC) adjuvant chemotherapy (CT) with and without darbepoetin alfa (Aranesp®) – Analysis serious adverse events

Authors :: Svjetlana Mohrmann
I. Zuna
U. Nitz
F. Werner
Claudia Schumacher
Toralf Reimer
Oleg Gluz
K. Ziegler
C. Oberhoff
M Warm
Source :: Geburtshilfe und Frauenheilkunde. 68
Publication Year :: 2008
Publisher :: Georg Thieme Verlag KG, 2008.

Subjects :: Oncology
medicine.medical_specialty
Darbepoetin alfa
business.industry
Adjuvant chemotherapy
Obstetrics and Gynecology
medicine.disease
Surgery
Breast cancer
Internal medicine
Maternity and Midwifery
medicine
Adverse effect
business
medicine.drug

Full Text Access

Tools